Accueil>>Signaling Pathways>> Microbiology & Virology>> HIV>>Zingibroside R1

Zingibroside R1 (Synonyms: Ginsenoside Z-R1, Polysciasaponin P5)

Catalog No.GC37968

Le zingibroside R1 est une saponine triterpénoÏde de type dammaranae, isolée des rhizomes, des racines pivotantes et des racines latérales de Panax japonicas C.

Products are for research use only. Not for human use. We do not sell to patients.

Zingibroside R1 Chemical Structure

Cas No.: 80930-74-1

Taille Prix Stock Qté
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Zingibroside R1 is dammaranae-type triterpenoid saponin, isolated from rhizomes, taproots, and lateral roots of Panax japonicas C. A. Meyer, shows excellent anti-tumor effects as well as anti-angiogenic activity[1].Zingibroside R1 possesses some anti-HIV-1 activity.Zingibroside R1 has inhibitory effects on the 2-deoxy-D-glucose (2-DG) uptake by EAT cells (IC50=91.3 μM)[2]. IC50: 91.3 μM (2-DG uptake)[1]

[1]. Yoshizaki K, et al. Saponins composition of rhizomes, taproots, and lateral roots of Satsuma-ninjin (Panax japonicus). Chem Pharm Bull (Tokyo). 2013;61(3):344-50. Epub 2012 Dec 28 [2]. Hasegawa H, et al. Inhibitory effect of some triterpenoid saponins on glucose transport in tumor cells and its application to in vitro cytotoxic and antiviral activities. Planta Med. 1994 Jun;60 (3):240-3.

Avis

Review for Zingibroside R1

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Zingibroside R1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.